Patents by Inventor Michael Grey
Michael Grey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11771688Abstract: Described herein are pyridine derivatives substituted by heterocycle and amino groups and pharmaceutical compositions comprising said compounds. The disclosed compounds are antifungal agents. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.Type: GrantFiled: June 24, 2019Date of Patent: October 3, 2023Assignee: AMPLYX PHARMACEUTICALS, INC.Inventors: Andrei W. Konradi, Jonathan A. Covel, Michael Grey
-
Publication number: 20230212211Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 23, 2022Publication date: July 6, 2023Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.Inventors: Bronislava GEDULIN, Michael GREY, Niall O'DONNELL
-
Publication number: 20220265649Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 27, 2022Publication date: August 25, 2022Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.Inventors: Bronislava GEDULIN, Michael Grey, Niall O'DONNELL
-
Patent number: 11376251Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 11, 2021Date of Patent: July 5, 2022Assignee: Shire Human Genetic Therapies, Inc.Inventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
-
Publication number: 20220023296Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 11, 2021Publication date: January 27, 2022Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.Inventors: Bronislava GEDULIN, Michael Grey, Niall O'DONNELL
-
Patent number: 11229661Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 11, 2019Date of Patent: January 25, 2022Assignee: SHIRE HUMAN GENETIC THERAPIES, INC.Inventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
-
Publication number: 20210290644Abstract: Provided herein are compositions and methods of use thereof for the treatment of fungal infections and diseases.Type: ApplicationFiled: August 30, 2019Publication date: September 23, 2021Inventors: Michael GREY, Jason BRITTAIN, Michael HODGES
-
Publication number: 20210275510Abstract: Described herein are pyridine derivatives substituted by heterocycle and amino groups and pharmaceutical compositions comprising said compounds. The disclosed compounds are antifungal agents. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.Type: ApplicationFiled: June 24, 2019Publication date: September 9, 2021Inventors: Andrei W. KONRADI, Jonathan A. COVEL, Michael GREY
-
Patent number: 10884516Abstract: The present invention discloses an operation and control apparatus for operating and controlling a personal computer and a control method therefor. The operation and control apparatus includes a touch unit and a control unit. The touch unit includes a touchpad, configured to sense an external tap behavior. The control unit includes a control module electrically connected to the touchpad and a memory module electrically connected to the control module. The memory module is configured to store at least one initial coordinate. The control module obtains the external tap behavior sensed by the touchpad, to generate a tap coordinate. The control module analyzes a position of the tap coordinate by using the initial coordinate as a basis point, to generate a control instruction for operating and controlling the personal computer.Type: GrantFiled: January 22, 2019Date of Patent: January 5, 2021Assignee: Corsair Memory, Inc.Inventor: Michael Grey
-
Publication number: 20200246366Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 11, 2019Publication date: August 6, 2020Applicant: Lumena Pharmaceuticals LLCInventors: Bronislava GEDULIN, Michael GREY, Niall O'DONNELL
-
Publication number: 20200207797Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 26, 2019Publication date: July 2, 2020Applicant: Lumena Pharmaceuticals LLCInventors: Bronislava GEDULIN, Michael GREY, Niall O'DONNELL
-
Publication number: 20200069715Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 11, 2019Publication date: March 5, 2020Applicant: Lumena Pharmaceuticals LLCInventors: Bronislava GEDULIN, Michael Grey, Niall O'Donnell
-
Patent number: 10512657Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 25, 2016Date of Patent: December 24, 2019Assignee: LUMENA PHARMACEUTIALS LLCInventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
-
Publication number: 20190227645Abstract: The present invention discloses an operation and control apparatus for operating and controlling a personal computer and a control method therefor. The operation and control apparatus includes a touch unit and a control unit. The touch unit includes a touchpad, configured to sense an external tap behavior. The control unit includes a control module electrically connected to the touchpad and a memory module electrically connected to the control module. The memory module is configured to store at least one initial coordinate. The control module obtains the external tap behavior sensed by the touchpad, to generate a tap coordinate. The control module analyzes a position of the tap coordinate by using the initial coordinate as a basis point, to generate a control instruction for operating and controlling the personal computer.Type: ApplicationFiled: January 22, 2019Publication date: July 25, 2019Inventor: Michael GREY
-
Publication number: 20190169217Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 10, 2018Publication date: June 6, 2019Applicant: Lumena Pharmaceuticals LLCInventors: Bronislava GEDULIN, Michael GREY, Niall O'DONNELL
-
Publication number: 20170368085Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 8, 2017Publication date: December 28, 2017Applicant: Lumena Pharmaceuticals LLCInventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
-
Publication number: 20160310518Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 25, 2016Publication date: October 27, 2016Applicant: Lumena Pharmaceuticals LLCInventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
-
Publication number: 20150119345Abstract: Provided herein are methods for treating or preventing gastrointestinal and/or liver infections utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists. Also provided herein are methods for increasing the levels of an enteroendocrine peptide or hormone in an individual suffering from a gastrointestinal infection or liver infection utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists.Type: ApplicationFiled: October 28, 2014Publication date: April 30, 2015Applicant: LUMENA PHARMACEUTICALS, INC.Inventors: Bronislava GEDULIN, Michael GREY
-
Publication number: 20140323412Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 26, 2012Publication date: October 30, 2014Inventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
-
Patent number: D870790Type: GrantFiled: June 20, 2018Date of Patent: December 24, 2019Assignee: Corsair Memory, Inc.Inventors: Dean Depay, Michael Grey